Marta Bosia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7017026/publications.pdf

Version: 2024-02-01

		304743	345221
89	1,605	22	36
papers	citations	h-index	g-index

97	97	97	2167
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	On the Implementation of Computerized Adaptive Observations for Psychological Assessment. Assessment, 2022, 29, 225-241.	3.1	3
2	Theory of mind and stereotypic behavior promote daily functioning in patients with schizophrenia. Australian and New Zealand Journal of Psychiatry, 2022, 56, 818-827.	2.3	4
3	Sustained symptomatic remission in schizophrenia: Course and predictors from a two-year prospective study. Schizophrenia Research, 2022, 239, 34-41.	2.0	3
4	It is time to address language disorders in schizophrenia: A RCT on the efficacy of a novel training targeting the pragmatics of communication (PragmaCom). Journal of Communication Disorders, 2022, 97, 106196.	1.5	18
5	Melatonin and aggressive behavior: A systematic review of the literature on preclinical and clinical evidence. Journal of Pineal Research, 2022, 72, .	7.4	7
6	Obsessive-compulsive symptoms moderates the effects of cognitive functioning on quality of life in clozapine-treated schizophrenia. Psychiatry Research Communications, 2022, , 100043.	1.0	0
7	Get up! Functional mobility and metabolic syndrome in chronic schizophrenia: Effects on cognition and quality of life. Schizophrenia Research: Cognition, 2022, 28, 100245.	1.3	0
8	Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art. Schizophrenia Research: Cognition, 2022, 29, 100249.	1.3	23
9	Cognitive remediation in schizophrenia: What happens after 10 years?. Schizophrenia Research: Cognition, 2022, 29, 100251.	1.3	2
10	Modeling the interplay of age at onset and sex on cognition in schizophrenia. Asian Journal of Psychiatry, 2022, , 103202.	2.0	3
11	Cognition in Schizophrenia: Modeling the Interplay between Interleukin-1Î² C-511T Polymorphism, Metabolic Syndrome, and Sex. Neuropsychobiology, 2021, 80, 321-332.	1.9	2
12	P.205 White matter integrity, clinical symptoms and quality of life in schizophrenia: a DTI study. European Neuropsychopharmacology, 2021, 44, S19-S20.	0.7	0
13	Clozapine tolerability in Treatment Resistant Schizophrenia: exploring the role of sex. Psychiatry Research, 2021, 297, 113698.	3.3	10
14	Functional benefits of co-occurring autistic symptoms in schizophrenia is delimited by symptom severity. Journal of Psychiatric Research, 2021, 137, 48-54.	3.1	9
15	Disentangling Cognitive Heterogeneity in Psychotic Spectrum Disorders. Asian Journal of Psychiatry, 2021, 60, 102651.	2.0	0
16	Eyes wide open: A systematic review of the association between insomnia and aggression in forensic contexts. International Journal of Law and Psychiatry, 2021, 78, 101734.	0.9	9
17	Longitudinal course of cognition in schizophrenia: Does treatment resistance play a role?. Journal of Psychiatric Research, 2021, 141, 346-352.	3.1	9
18	Communicative-pragmatic abilities mediate the relationship between cognition and daily functioning in schizophrenia.. Neuropsychology, 2021, 35, 42-56.	1.3	15

#	Article	IF	Citations
19	Cognitive Remediation for Inpatients With Schizophrenia. Journal of Nervous and Mental Disease, 2021, 209, 76-81.	1.0	1
20	The role of genetics in cognitive remediation in schizophrenia: A systematic review. Schizophrenia Research: Cognition, 2020, 19, 100146.	1.3	4
21	The Influence of Premorbid Adjustment and Autistic Traits on Social Cognitive Dysfunction in Schizophrenia. Journal of the International Neuropsychological Society, 2020, 26, 276-285.	1.8	16
22	The association of autistic traits with Theory of Mind and its training efficacy in patients with schizophrenia. Schizophrenia Research: Cognition, 2020, 19, 100164.	1.3	6
23	M51. EFFICACY OF â€œPRAGMACOM TRAININGâ€•IN SCHIZOPHRENIA: A RCT ON A NOVEL PRAGMATIC INTERVENTION. Schizophrenia Bulletin, 2020, 46, S153-S153.	4.3	1
24	M202. SEX-RELATED DIFFERENCES IN CLOZAPINE SIDE EFFECTS IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S213-S213.	4.3	1
25	S67. TREATMENT-RESISTANCE AFFECTS LONG-TERM COGNITIVE TRAJECTORIES IN SCHIZOPHRENIA: A LONGITUDINAL STUDY. Schizophrenia Bulletin, 2020, 46, S59-S59.	4.3	0
26	A leopard cannot change its spots: A novel pragmatic account of concretism in schizophrenia. Neuropsychologia, 2020, 139, 107332.	1.6	25
27	Stability and generalization of combined theory of mind and cognitive remediation interventions in schizophrenia: Follow-up results.. Psychiatric Rehabilitation Journal, 2020, 43, 140-148.	1.1	5
28	Schizophrenia, cannabis use and Catechol-O-Methyltransferase (COMT): Modeling the interplay on cognition. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 363-368.	4.8	9
29	Daily Functioning in Schizophrenia. Journal of Nervous and Mental Disease, 2019, 207, 615-619.	1.0	4
30	From cognitive and clinical substrates to functional profiles: Disentangling heterogeneity in schizophrenia. Psychiatry Research, 2019, 271, 446-453.	3.3	17
31	The role of premorbid adjustment in schizophrenia: Focus on cognitive remediation outcome. Neuropsychological Rehabilitation, 2019, 29, 1611-1624.	1.6	11
32	Intellectual and cognitive profiles in patients affected by schizophrenia. Journal of Neuropsychology, 2019, 13, 589-602.	1.4	24
33	Exploring predictors of work competence in schizophrenia: The role of theory of mind. Neuropsychological Rehabilitation, 2019, 29, 691-703.	1.6	7
34	Cognitive Reserve Profiles in Chronic Schizophrenia: Effects on Theory of Mind Performance and Improvement after Training. Journal of the International Neuropsychological Society, 2018, 24, 563-571.	1.8	18
35	Visual and audio emotion processing training for outpatients with schizophrenia: an integrated multisensory approach. Neuropsychological Rehabilitation, 2018, 28, 1131-1144.	1.6	6
36	Integrated cognitive remediation and standard rehabilitation therapy in patients of schizophrenia: persistence after 5 years. Schizophrenia Research, 2018, 192, 335-339.	2.0	35

#	Article	IF	Citations
37	Achieving recovery in patients with schizophrenia through psychosocial interventions: <scp>A</scp> retrospective study. Psychiatry and Clinical Neurosciences, 2018, 72, 28-34.	1.8	20
38	Improving Cognition to Increase Treatment Efficacy in Schizophrenia: Effects of Metabolic Syndrome on Cognitive Remediation's Outcome. Frontiers in Psychiatry, 2018, 9, 647.	2.6	17
39	Exploring anxiety in schizophrenia: New light on a hidden figure. Psychiatry Research, 2018, 268, 312-316.	3.3	11
40	Neurobiology of cognitive remediation in schizophrenia: Effects of EAAT2 polymorphism. Schizophrenia Research, 2018, 202, 106-110.	2.0	12
41	Can patients with schizophrenia have good mentalizing skills? Disentangling heterogeneity of theory of mind.. Neuropsychology, 2018, 32, 746-753.	1.3	10
42	Exploring functioning in schizophrenia: Predictors of functional capacity and real-world behaviour. Psychiatry Research, 2017, 251, 118-124.	3.3	58
43	Is longer treatment better? A comparison study of 3 versus 6 months cognitive remediation in schizophrenia.. Neuropsychology, 2017, 31, 467-473.	1.3	12
44	Targeting anxiety to improve quality of life in patients with schizophrenia. European Psychiatry, 2017, 45, 129-135.	0.2	23
45	Cognitive Remediation and Functional Improvement in Schizophrenia: is it a Matter of Size?. European Psychiatry, 2017, 40, 26-32.	0.2	23
46	The communicative impairment as a core feature of schizophrenia: Frequency of pragmatic deficit, cognitive substrates, and relation with quality of life. Comprehensive Psychiatry, 2016, 71, 106-120.	3.1	108
47	ADDing a piece to the puzzle of cognition in schizophrenia. European Journal of Medical Genetics, 2016, 59, 26-31.	1.3	11
48	Combined social cognitive and neurocognitive rehabilitation strategies in schizophrenia: neuropsychological and psychopathological influences on Theory of Mind improvement. Psychological Medicine, 2015, 45, 3147-3157.	4.5	34
49	COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: effects on the negative symptom response to clozapine. Pharmacogenomics, 2015, 16, 35-44.	1.3	37
50	Detecting syntactic and semantic anomalies in schizophrenia. Neuropsychologia, 2015, 79, 147-157.	1.6	37
51	Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back. Expert Opinion on Drug Discovery, 2015, 10, 125-139.	5.0	15
52	Tough Love: Sexuality, Compassion, and the Christian Right. By Cynthia Burack . Albany, NY: SUNY Press, 2014. 257 pp. $85.00 cloth. $29.95 eBook. Politics and Religion, 2015, 8, 181-183.	0.8	0
53	Combined Neurocognitive And Metacognitive Rehabilitation In Schizophrenia: Effects On Bias Against Disconfirmatory Evidence. European Psychiatry, 2015, 30, 615-621.	0.2	19
54	COMT and STH polymorphisms interaction on cognition in schizophrenia. Neurological Sciences, 2015, 36, 215-220.	1.9	12

#	Article	IF	Citations
55	Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances. Schizophrenia Research: Cognition, 2014, 1, 187-192.	1.3	9
56	Research Highlights: Highlights from the latest articles on the pharmacogenomics of neuropsychiatric disorders. Pharmacogenomics, 2014, 15, 735-738.	1.3	0
57	COMT and 5-HT1A-receptor genotypes potentially affect executive functions improvement after cognitive remediation in schizophrenia. Health Psychology and Behavioral Medicine, 2014, 2, 509-516.	1.8	19
58	Exploring effects of EAAT polymorphisms on cognitive functions in schizophrenia. Pharmacogenomics, 2014, 15, 925-932.	1.3	25
59	P.3.b.034 Interaction of EAAT2 genotype and clozapine on cognitive remediation outcome. European Neuropsychopharmacology, 2014, 24, S511.	0.7	0
60	Factors affecting cognitive remediation response in schizophrenia: The role of COMT gene and antipsychotic treatment. Psychiatry Research, 2014, 217, 9-14.	3.3	57
61	Effect of glutamate transporter EAAT2 gene variants and gray matter deficits on working memory in schizophrenia. European Psychiatry, 2014, 29, 219-225.	0.2	28
62	Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders. BMC Psychiatry, 2013, 13, 235.	2.6	20
63	Catechol-O-methyltransferase (COMT) genotype biases neural correlates of empathy and perceived personal distress in schizophrenia. Comprehensive Psychiatry, 2013, 54, 181-186.	3.1	16
64	P.3.b.029 Antipsychotics, metabolic syndrome and schizophrenia: investigating the role of SREBF polymorphisms. European Neuropsychopharmacology, 2013, 23, S446.	0.7	0
65	Theory of Mind intervention for outpatients with schizophrenia. Neuropsychological Rehabilitation, 2013, 23, 383-400.	1.6	47
66	Research Highlights: Highlights from the latest research in mood disorder pharmacogenomics. Pharmacogenomics, 2013, 14, 127-130.	1.3	1
67	Neurofunctional Correlates of Theory of Mind Deficits in Schizophrenia. Current Topics in Medicinal Chemistry, 2012, 12, 2284-2302.	2.1	39
68	S.09.02 Predicting cognitive remediation outcome with genes. European Neuropsychopharmacology, 2012, 22, S125-S126.	0.7	0
69	P.3.a.014 Exploring the effect of genetic variability of adducins on cognition in schizophrenia. European Neuropsychopharmacology, 2012, 22, S311-S312.	0.7	0
70	Saitohin polymorphism and executive dysfunction in schizophrenia. Neurological Sciences, 2012, 33, 1051-1056.	1.9	8
71	Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. European Psychiatry, 2012, 27, 396-400.	0.2	24
72	Self-awareness of cognitive functioning in schizophrenia: Patients and their relatives. Psychiatry Research, 2012, 198, 207-211.	3.3	25

#	Article	IF	Citations
73	Theory of mind and emotion processing training for patients with schizophrenia: Preliminary findings. Psychiatry Research, 2012, 198, 371-377.	3.3	62
74	Patterns of evidence integration in schizophrenia and delusion. Psychiatry Research, 2012, 200, 108-114.	3.3	24
75	Cognitive dysfunction and glutamate reuptake: Effect of EAAT2 polymorphism in schizophrenia. Neuroscience Letters, 2012, 522, 151-155.	2.1	53
76	9-OH risperidone response in risperidone poor responders: An open study of drug response concordance. Neurology Psychiatry and Brain Research, 2012, 18, 109-113.	2.0	2
77	Effect of 5-HT1A-receptor functional polymorphism on Theory of Mind performances in schizophrenia. Psychiatry Research, 2011, 188, 187-190.	3.3	23
78	P.3.a.016 Effects of catechol-O-methyltransferase Val108/158Met and Saitohin q7r polymorphisms on cognitive functions in schizophrenia. European Neuropsychopharmacology, 2011, 21, S462.	0.7	0
79	Computer-aided neurocognitive remediation in schizophrenia: Durability of rehabilitation outcomes in a follow-up study. Neuropsychological Rehabilitation, 2010, 20, 659-674.	1.6	33
80	EXECUTIVE DYSFUNCTION IN SCHIZOPHRENIA: POSSIBLE ROLE OF SAITOHIN GENE. Schizophrenia Research, 2010, 117, 217.	2.0	0
81	HTTLPR functional polymorphism in schizophrenia: Executive functions vs. sustained attention dissociation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 81-85.	4.8	31
82	Functional and structural brain correlates of theory of mind and empathy deficits in schizophrenia. Schizophrenia Research, 2009, 114, 154-160.	2.0	137
83	â€˜Theoryâ€™ of mind impairment in patients affected by schizophrenia and in their parents. Schizophrenia Research, 2009, 115, 278-285.	2.0	57
84	P.3.14 Association study of COMT Val108/158Met polymorphism and treatment response to haloperidol, risperidone and clozapine. European Neuropsychopharmacology, 2009, 19, S73-S74.	0.7	2
85	P.3.c.063 Effect of 5-HT1a and catechol-O-methyl-transferase gene polymorphisms on negative symptom response to clozapine. European Neuropsychopharmacology, 2009, 19, S546-S547.	0.7	0
86	Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia. Neuroscience Letters, 2007, 417, 271-274.	2.1	90
87	P.3.12 Association study of GSK-3Î² â˜’50T/C polymorphism with executive performances in schizophrenia. European Neuropsychopharmacology, 2007, 17, S79.	0.7	0
88	Communication in schizophrenia, between pragmatics, cognition, and social cognition. Linguistik Aktuell, 0, , 213-234.	0.6	7
89	Targeting the communicative impairment in schizophrenia with a neuropragmatic approach. Frontiers in Psychology, 0, 8, .	2.1	0